ELREXFIO
(Elranatamab-bcmm)Phase 2Biologic
ELREXFIO is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Belamaf
GSKPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Aug 14, 2023
ELREXFIO
BLA BLA761345
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Elranatamab-bcmm. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details